Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial.

Autor: Allahyari, Abolghasem1 (AUTHOR), Ehsanpour, Ali2 (AUTHOR), Najafi, Behrouz3 (AUTHOR), Ansarinejad, Nafiseh4 (AUTHOR), Mehrzad, Valiollah5 (AUTHOR), Kalantari, Behjat6 (AUTHOR), Raafat, Jahangir7 (AUTHOR), Ghadiany, Mojtaba8 (AUTHOR), Shahi, Farhad9 (AUTHOR), Gharib, Behrooz10 (AUTHOR), Moazed, Vahid11 (AUTHOR), Khosravi, Adnan12 (AUTHOR), Mirpour, Mir Hossein13 (AUTHOR), Salari, Sina14 (AUTHOR), Mortazavizadeh, Seyedmohammadreza15 (AUTHOR), Nekoyi, Amirabbas16 (AUTHOR), Khani, Mohsen17 (AUTHOR), Sadeghi, Alireza18 (AUTHOR), Gharib, Sirus19 (AUTHOR), Bary, Alireza20 (AUTHOR)
Zdroj: BMC Cancer. 12/22/2022, Vol. 22 Issue 1, p1-10. 10p.
Databáze: Academic Search Ultimate
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje